Views: 1,387 | Downloads:
21
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Evolution of Medical Services far HIVJAWS in thailand
Kunanusont C 
Background: Thailand started the anti-retroviral supply program in 1992 primarily for low
income groups. The budget has increased but coverage has decreased due to the large number of
cases requesting supply. Rapid advancement of HIV therapy has resulted in higher drug cost which
is not affordable to people in developing countries. The cost effectiveness review in 1995, conducted
by staff of the World Bank, World Health Organization, and Ministry of Public Health
(MOPH), demonstrated high cost with limited benefit. It encouraged program evolution, from "supply
for services" to "supply for research". Faced with an expanding AIDS epidemic and economic set
back, Thailand has to adapt its program to fit scientific, ethic, and economic situations.
Activities: The program now extends to (a) adapting current therapeutic regimens, (b)
developing new treatment and (c) natural history study of people with HIV/AIDS who receive antiretrovirals
(ARV), anti-opportunistic infections (anti Ols), or alternative care. Laboratory issues,
and prevention activities are also included. To allocate an approximately 300 million baht budget
each year, participating hospitals were invited to submit proposals for consideration. Proposals
were ranked and supported according to scores and research priority. A clinical research network
was set up in 1996 and supply was shipped out in 1997 on double combination for I ,200 cases, with
triple combination for 40 cases, all in 58 sites. Investigators were trained for Good Clinical Practices
(GCP) to reassure data handling quality. Psychological and social support were encouraged
through the health system research network. Until 15 Jan 98, 49 proposals were submitted (42
ARV, 1 herbal medicine, 6 pediatrics/perinatals). A working group consisting of local experts
from medical schools, and the MOPH together ranked these proposals. Those with high scores
received medical supplies while the low scores received technological advice in order to increase
their capability to participate in research in the near future.
Conclusions: Central supply encouraged physicians to treat more cases but discouraged
their hospitals to set up their own budget. The clinical research network allowed team and infrastructure
building up which can be adapted for drug, vaccine trials and observational databases.
More training is needed. For other developing countries, Thailand's experiences should be perceived
as an example not a model.
Key word: HIV, AIDS, Clinical Trial, Medical Supply, Thailand
income groups. The budget has increased but coverage has decreased due to the large number of
cases requesting supply. Rapid advancement of HIV therapy has resulted in higher drug cost which
is not affordable to people in developing countries. The cost effectiveness review in 1995, conducted
by staff of the World Bank, World Health Organization, and Ministry of Public Health
(MOPH), demonstrated high cost with limited benefit. It encouraged program evolution, from "supply
for services" to "supply for research". Faced with an expanding AIDS epidemic and economic set
back, Thailand has to adapt its program to fit scientific, ethic, and economic situations.
Activities: The program now extends to (a) adapting current therapeutic regimens, (b)
developing new treatment and (c) natural history study of people with HIV/AIDS who receive antiretrovirals
(ARV), anti-opportunistic infections (anti Ols), or alternative care. Laboratory issues,
and prevention activities are also included. To allocate an approximately 300 million baht budget
each year, participating hospitals were invited to submit proposals for consideration. Proposals
were ranked and supported according to scores and research priority. A clinical research network
was set up in 1996 and supply was shipped out in 1997 on double combination for I ,200 cases, with
triple combination for 40 cases, all in 58 sites. Investigators were trained for Good Clinical Practices
(GCP) to reassure data handling quality. Psychological and social support were encouraged
through the health system research network. Until 15 Jan 98, 49 proposals were submitted (42
ARV, 1 herbal medicine, 6 pediatrics/perinatals). A working group consisting of local experts
from medical schools, and the MOPH together ranked these proposals. Those with high scores
received medical supplies while the low scores received technological advice in order to increase
their capability to participate in research in the near future.
Conclusions: Central supply encouraged physicians to treat more cases but discouraged
their hospitals to set up their own budget. The clinical research network allowed team and infrastructure
building up which can be adapted for drug, vaccine trials and observational databases.
More training is needed. For other developing countries, Thailand's experiences should be perceived
as an example not a model.
Key word: HIV, AIDS, Clinical Trial, Medical Supply, Thailand
Download:
PDF